Galmed Pharmaceuticals (GLMD)

• Market cap: $5.05M
• 1 day: -0.65%
• 5 days: -1.93%
• 1 month: 3.04%
• 3 months: -67.38%
• 6 months: -19.74%
• Year to date: -42.23%
• 1 year: -36.46%
• 5 years: -99.70%
• 10 years: -99.72%

About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

6.44% less ownership

Funds ownership: 6.81% [Q2] → 0.37% (-6.44%) [Q3]

23% less funds holding

Funds holding: 13 [Q2] → 10 (-3) [Q3]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

69% less capital invested

Capital invested by funds: $123K [Q2] → $38.3K (-$84.6K) [Q3]

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7